Cantor Fitzgerald Issues Positive Forecast for KALV Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Cantor Fitzgerald upped their FY2026 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a report issued on Monday, July 14th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the specialty pharmaceutical company will post earnings of ($2.83) per share for the year, up from their prior estimate of ($2.90). The consensus estimate for KalVista Pharmaceuticals' current full-year earnings is ($3.56) per share.

Several other research analysts have also issued reports on the company. Leerink Partners increased their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday, July 7th. HC Wainwright increased their price target on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. JMP Securities increased their price objective on KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a research note on Tuesday, July 8th. Finally, Jones Trading reissued a "buy" rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $26.29.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $15.17 on Wednesday. The business's 50 day simple moving average is $12.67 and its two-hundred day simple moving average is $11.34. The firm has a market cap of $757.80 million, a P/E ratio of -4.11 and a beta of -0.04. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $16.32.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same quarter in the prior year, the company posted ($1.07) earnings per share.

Institutional Trading of KalVista Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Suvretta Capital Management LLC increased its position in KalVista Pharmaceuticals by 16.6% in the fourth quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company's stock worth $41,613,000 after buying an additional 701,007 shares during the last quarter. Tang Capital Management LLC increased its position in KalVista Pharmaceuticals by 13.2% in the fourth quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company's stock worth $41,451,000 after buying an additional 572,300 shares during the last quarter. Frazier Life Sciences Management L.P. increased its position in KalVista Pharmaceuticals by 32.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock worth $41,400,000 after buying an additional 1,200,000 shares during the last quarter. Vestal Point Capital LP increased its position in KalVista Pharmaceuticals by 19.3% in the fourth quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock worth $40,402,000 after buying an additional 770,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of KalVista Pharmaceuticals by 1.9% in the first quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company's stock worth $26,526,000 after acquiring an additional 43,355 shares during the period.

Insider Buying and Selling

In related news, CEO Benjamin L. Palleiko sold 32,979 shares of the stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the sale, the chief executive officer directly owned 369,595 shares of the company's stock, valued at approximately $5,798,945.55. This trade represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Paul K. Audhya sold 2,776 shares of the firm's stock in a transaction on Monday, May 19th. The stock was sold at an average price of $11.84, for a total value of $32,867.84. Following the completion of the sale, the insider directly owned 106,611 shares of the company's stock, valued at $1,262,274.24. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,878 shares of company stock valued at $723,617 over the last ninety days. 10.50% of the stock is currently owned by company insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.